Matches in SemOpenAlex for { <https://semopenalex.org/work/W2279782480> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2279782480 endingPage "359" @default.
- W2279782480 startingPage "354" @default.
- W2279782480 abstract "Since resistance of pathogenic bacteria towards available antibiotics has become a major worldwide problem, the design of new compounds to deal with resistant bacteria is one of the most important areas of antibacterial research today. As it is known about the wide spectrum biological activities of fused pyrimidine including antimicrobial activity, it has been thought worthwhile to synthesis thienopyrimidines. In search for new biodynamic potent molecule, it was thought useful to attach 1,3,4-oxadiazoles which are also lead molecules against microbes and in the present study 1,3,4-oxadiazole attached to thienopyrimidine nucleus. Various 4-(5-sustituted-[1,3,4]oxadiazol-2-ylmethoxy)-thieno[2,3-d]pyrimidines have been synthesized by means of reported methods and all the test compounds was assayed in vitro for antibacterial activity against two different Gram-negative (K. pneumoniae MTCC 39 and S. typhi CNCTC 786) and Gram-positive (S. aureus ATCC 3750, Bacillus subtilis MTCC 121) bacteria each and for antifungal activity against Candida albicans (MTCC 183). The MIC was determined by Rezasurin microplate method. The structure of 4-[(5-substituted-1,3,4-oxadiazol-2-yl)methoxy] thieno[2,3-d]pyrimidines (7a-7j) has been confirmed by spectral studies. Among the compounds tested for antimicrobial activity, four compounds 7(c, d, e, j) have shown potent activity against Gram-positive S. aureus with MIC value below 3.9 μg/ml. Compounds 7c and 7d have shown better activity towards Bacillus subtilis too. Compounds 7c and 7e have shown better activity against Candida albicans with the MIC values 125 μg/ml. The newly synthesized compounds are active against S. aureus specifically. Though the MIC values obtained for G –ve bacteria and Fungus, are large, the study proves that the class of thienopyrimidines can potentially serve as lead structure for further optimization." @default.
- W2279782480 created "2016-06-24" @default.
- W2279782480 creator A5016464990 @default.
- W2279782480 creator A5053601192 @default.
- W2279782480 creator A5075419196 @default.
- W2279782480 date "2013-04-28" @default.
- W2279782480 modified "2023-09-25" @default.
- W2279782480 title "Synthesis, spectral studies and evaluation of 4-(5-substituted-[1,3,4] oxadiazol-2-ylmethoxy)-thieno[2,3-d]pyrimidines as novel antimicrobials" @default.
- W2279782480 hasPublicationYear "2013" @default.
- W2279782480 type Work @default.
- W2279782480 sameAs 2279782480 @default.
- W2279782480 citedByCount "0" @default.
- W2279782480 crossrefType "journal-article" @default.
- W2279782480 hasAuthorship W2279782480A5016464990 @default.
- W2279782480 hasAuthorship W2279782480A5053601192 @default.
- W2279782480 hasAuthorship W2279782480A5075419196 @default.
- W2279782480 hasConcept C145081991 @default.
- W2279782480 hasConcept C178790620 @default.
- W2279782480 hasConcept C185592680 @default.
- W2279782480 hasConcept C202751555 @default.
- W2279782480 hasConcept C2777272437 @default.
- W2279782480 hasConcept C2779321679 @default.
- W2279782480 hasConcept C2780104969 @default.
- W2279782480 hasConcept C2780917455 @default.
- W2279782480 hasConcept C4937899 @default.
- W2279782480 hasConcept C501593827 @default.
- W2279782480 hasConcept C523546767 @default.
- W2279782480 hasConcept C54355233 @default.
- W2279782480 hasConcept C55493867 @default.
- W2279782480 hasConcept C71240020 @default.
- W2279782480 hasConcept C86803240 @default.
- W2279782480 hasConcept C89423630 @default.
- W2279782480 hasConceptScore W2279782480C145081991 @default.
- W2279782480 hasConceptScore W2279782480C178790620 @default.
- W2279782480 hasConceptScore W2279782480C185592680 @default.
- W2279782480 hasConceptScore W2279782480C202751555 @default.
- W2279782480 hasConceptScore W2279782480C2777272437 @default.
- W2279782480 hasConceptScore W2279782480C2779321679 @default.
- W2279782480 hasConceptScore W2279782480C2780104969 @default.
- W2279782480 hasConceptScore W2279782480C2780917455 @default.
- W2279782480 hasConceptScore W2279782480C4937899 @default.
- W2279782480 hasConceptScore W2279782480C501593827 @default.
- W2279782480 hasConceptScore W2279782480C523546767 @default.
- W2279782480 hasConceptScore W2279782480C54355233 @default.
- W2279782480 hasConceptScore W2279782480C55493867 @default.
- W2279782480 hasConceptScore W2279782480C71240020 @default.
- W2279782480 hasConceptScore W2279782480C86803240 @default.
- W2279782480 hasConceptScore W2279782480C89423630 @default.
- W2279782480 hasIssue "4" @default.
- W2279782480 hasOpenAccess W2279782480 @default.
- W2279782480 hasRelatedWork W1518356544 @default.
- W2279782480 hasRelatedWork W1922504649 @default.
- W2279782480 hasRelatedWork W1968713313 @default.
- W2279782480 hasRelatedWork W1999631834 @default.
- W2279782480 hasRelatedWork W2027298984 @default.
- W2279782480 hasRelatedWork W2041427670 @default.
- W2279782480 hasRelatedWork W2047046246 @default.
- W2279782480 hasRelatedWork W2055559435 @default.
- W2279782480 hasRelatedWork W2118854404 @default.
- W2279782480 hasRelatedWork W2123507023 @default.
- W2279782480 hasRelatedWork W2159669055 @default.
- W2279782480 hasRelatedWork W2160235755 @default.
- W2279782480 hasRelatedWork W2189136145 @default.
- W2279782480 hasRelatedWork W2262774711 @default.
- W2279782480 hasRelatedWork W2469882285 @default.
- W2279782480 hasRelatedWork W2474079311 @default.
- W2279782480 hasRelatedWork W2592881970 @default.
- W2279782480 hasRelatedWork W2991051472 @default.
- W2279782480 hasRelatedWork W2011518357 @default.
- W2279782480 hasRelatedWork W2151367560 @default.
- W2279782480 hasVolume "6" @default.
- W2279782480 isParatext "false" @default.
- W2279782480 isRetracted "false" @default.
- W2279782480 magId "2279782480" @default.
- W2279782480 workType "article" @default.